Connection

GUILLERMINA LOZANO to Nuclear Proteins

This is a "connection" page, showing publications GUILLERMINA LOZANO has written about Nuclear Proteins.
Connection Strength

3.948
  1. Daxx Functions Are p53-Independent In Vivo. Mol Cancer Res. 2018 10; 16(10):1523-1529.
    View in: PubMed
    Score: 0.278
  2. Tumorigenesis promotes Mdm4-S overexpression. Oncotarget. 2017 Apr 18; 8(16):25837-25847.
    View in: PubMed
    Score: 0.257
  3. p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis. Mol Cancer Res. 2016 Jan; 14(1):56-65.
    View in: PubMed
    Score: 0.232
  4. Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma. Oncogene. 2016 Jan 21; 35(3):358-65.
    View in: PubMed
    Score: 0.224
  5. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat. 2014 Jun; 35(6):728-37.
    View in: PubMed
    Score: 0.207
  6. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol. 2007 Oct; 38(10):1553-62.
    View in: PubMed
    Score: 0.131
  7. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res. 2006 Oct 01; 66(19):9502-8.
    View in: PubMed
    Score: 0.124
  8. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene. 2004 Oct 07; 23(46):7644-50.
    View in: PubMed
    Score: 0.108
  9. Model predictions of MDM2 mediated cell regulation. Cell Cycle. 2004 May; 3(5):655-61.
    View in: PubMed
    Score: 0.105
  10. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res. 2003 Dec 15; 63(24):8664-9.
    View in: PubMed
    Score: 0.102
  11. MDM2, an introduction. Mol Cancer Res. 2003 Dec; 1(14):993-1000.
    View in: PubMed
    Score: 0.102
  12. Disrupting TP53 in mouse models of human cancers. Hum Mutat. 2003 Mar; 21(3):321-6.
    View in: PubMed
    Score: 0.096
  13. Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland. Oncogene. 2002 May 16; 21(22):3525-31.
    View in: PubMed
    Score: 0.091
  14. Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis. 2002 Feb; 32(2):145-7.
    View in: PubMed
    Score: 0.089
  15. Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer. Nat Commun. 2021 09 10; 12(1):5389.
    View in: PubMed
    Score: 0.087
  16. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet. 2001 Sep; 29(1):92-5.
    View in: PubMed
    Score: 0.087
  17. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene. 2001 Jul 05; 20(30):4041-9.
    View in: PubMed
    Score: 0.086
  18. Organization, expression, and localization of the murine mdmx gene and pseudogene. Gene. 2001 May 30; 270(1-2):277-83.
    View in: PubMed
    Score: 0.085
  19. p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis. 2001 May; 22(5):729-35.
    View in: PubMed
    Score: 0.085
  20. Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo. Sci Adv. 2020 08; 6(32):eaba8415.
    View in: PubMed
    Score: 0.081
  21. The loss of mdm2 induces p53-mediated apoptosis. Oncogene. 2000 Mar 23; 19(13):1691-7.
    View in: PubMed
    Score: 0.079
  22. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol. 1999 Jul; 188(3):322-8.
    View in: PubMed
    Score: 0.075
  23. Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. Cell Growth Differ. 1999 Mar; 10(3):147-54.
    View in: PubMed
    Score: 0.073
  24. MDM2 function. Biochim Biophys Acta. 1998 Apr 17; 1377(2):M55-9.
    View in: PubMed
    Score: 0.069
  25. The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene. 1997 Sep 25; 15(13):1527-34.
    View in: PubMed
    Score: 0.066
  26. Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nat Genet. 1997 Aug; 16(4):336-7.
    View in: PubMed
    Score: 0.065
  27. Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest. Radiat Res. 1997 Aug; 148(2):115-22.
    View in: PubMed
    Score: 0.065
  28. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. Cold Spring Harb Perspect Med. 2016 08 01; 6(8).
    View in: PubMed
    Score: 0.061
  29. The organization and expression of the mdm2 gene. Genomics. 1996 May 01; 33(3):352-7.
    View in: PubMed
    Score: 0.060
  30. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene. 2016 09 08; 35(36):4798-806.
    View in: PubMed
    Score: 0.059
  31. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995 Nov 09; 378(6553):203-6.
    View in: PubMed
    Score: 0.058
  32. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice. J Hepatol. 2015 Feb; 62(2):371-9.
    View in: PubMed
    Score: 0.054
  33. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle. 2013 Jun 01; 12(11):1722-31.
    View in: PubMed
    Score: 0.049
  34. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell. 2010 Sep 14; 18(3):220-30.
    View in: PubMed
    Score: 0.041
  35. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One. 2010 May 26; 5(5):e10813.
    View in: PubMed
    Score: 0.040
  36. The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev. 2007 Feb; 17(1):66-70.
    View in: PubMed
    Score: 0.031
  37. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol. 2007 Jan; 20(1):54-62.
    View in: PubMed
    Score: 0.031
  38. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Cancer Lett. 2005 Oct 18; 228(1-2):21-7.
    View in: PubMed
    Score: 0.029
  39. Gankyrin: an intriguing name for a novel regulator of p53 and RB. Cancer Cell. 2005 Jul; 8(1):3-4.
    View in: PubMed
    Score: 0.028
  40. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004 Dec 17; 119(6):861-72.
    View in: PubMed
    Score: 0.027
  41. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 Nov 24; 119(5):591-602.
    View in: PubMed
    Score: 0.027
  42. Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene. 2002 Oct 10; 21(46):7100-13.
    View in: PubMed
    Score: 0.023
  43. Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas. Dis Model Mech. 2022 08 01; 15(8).
    View in: PubMed
    Score: 0.023
  44. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem. 2002 May 31; 277(22):19251-4.
    View in: PubMed
    Score: 0.023
  45. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 2000 Sep 15; 14(18):2358-65.
    View in: PubMed
    Score: 0.020
  46. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene. 2000 Jan 20; 19(3):358-64.
    View in: PubMed
    Score: 0.019
  47. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 1999 Apr 01; 18(7):1805-14.
    View in: PubMed
    Score: 0.018
  48. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 1997 Mar 15; 11(6):714-25.
    View in: PubMed
    Score: 0.016
  49. mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene. 1996 Oct 17; 13(8):1731-6.
    View in: PubMed
    Score: 0.015
  50. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol. 1994 Oct; 14(10):6858-67.
    View in: PubMed
    Score: 0.013
  51. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science. 1990 Aug 31; 249(4972):1049-51.
    View in: PubMed
    Score: 0.010
  52. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One. 2008; 3(11):e3707.
    View in: PubMed
    Score: 0.009
  53. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol. 2005 Jun; 19(6):1646-53.
    View in: PubMed
    Score: 0.007
  54. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res. 2004 Dec 15; 64(24):9080-5.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.